Adaptations to chronic rapamycin in mice

References

• Wilkinson JE, Burmeister L, Brooks SV, Chan CC, Friedline S, Harrison DE, etal. Rapamycin slows aging in mice. Aging Cell. 2012; 11: 675–82.
   Google Scholar
• Zhang Y, Bokov A, Gelfond J, Soto V, Ikeno Y, Hubbard G, etal. Rapamycin extends life and health in C57BL/6 mice. J Gerontol A Biol Sci Med Sci. 2014; 69(2): 119–30.
   Google Scholar
• Harrison DE, Strong R, Sharp ZD, Nelson JF, Astle CM, Flurkey K, etal. Rapamycin fed late in life extends lifespan in genetically heterogeneous mice. Nature. 2009; 460: 392–5. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, De Cabo R, etal. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2011; 66(2): 191–201.
   Google Scholar
• Neff F, Flores-dominguez D, Ryan DP, Horsch M, Schroder S, Adler T, etal. Rapamycin extends murine lifespan but has limited effects on aging. J Clin Invest. 2013; 123(8): 1–2.
   Web of Science ®Google Scholar
• Miller RA, Harrison DE, Astle CM, Fernandez E, Flurkey K, Han M, etal. Rapamycin-mediated lifespan increase in mice is dose and sex dependent and metabolically distinct from dietary restriction. Aging Cell. 2014; 13(3): 468–77.
   Google Scholar
• Hasty P, Livi CB, Dodds SG, Jones D, Strong R, Javors M, etal. ERapa restores a normal life span in a FAP mouse model. Cancer Prev Res. 2014; 7: 169–78.
   Web of Science ®Google Scholar
• Livi CB, Hardman RL, Christy BA, Dodds SG, Jones D, Williams C, etal. Rapamycin extends life span of Rb1 + /( mice by inhibiting neuroendocrine tumors. Aging (Albany NY). 2013; 5(2): 100–10.
   Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, etal. Rapamycin extends maximal lifespan in cancer-prone mice. Am J Pathol. 2010; 176(5): 2092–7.
   Google Scholar
• Anisimov VN, Zabezhinski MA, Popovich IG, Piskunova TS, Semenchenko AV, Tyndyk ML, etal. Rapamycin increases lifespan and inhibits spontaneous tumorigenesis in inbred female mice. Cell Cycle. 2011; 10(24): 4230–6.
   Google Scholar
• Comas M, Toshkov I, Kuropatwinski KK, Chernova OB, Polinsky A, Blagosklonny MV, etal. New nanoformulation of rapamycin rapatar extends lifespan in homozygous p53 − /− mice by delaying carcinogenesis. Aging (Albany NY). 2012; 4(10): 715–22.
   Google Scholar
• Komarova EA, Antoch MP, Novototskaya LR, Chernova OB, Paszkiewicz G, Leontieva OV, etal. Rapamycin extends lifespan and delays tumorigenesis in heterozygous p53+/−mice. Aging (Albany NY). 2012; 4(10): 709–14.
   Google Scholar
• Dao V, Pandeswara S, Liu Y, Hurez V, Dodds S, Callaway D, etal. Prevention of carcinogen and inflammation-induced dermal cancer by oral rapamycin includes reducing genetic damage. Cancer Prev Res (Phila). 2015; 8(5): 400–9.
   Google Scholar
• Rho O, Kiguchi K, Jiang G, Digiovanni J. Impact of mTORC1 inhibition on keratinocyte proliferation during skin tumor promotion in wild-type and BK5.AktWT mice. Mol Carcinog. 2013; 12: 1–12.
   Google Scholar
• Saha A, Blando J, Tremmel L, DiGiovanni J. Effect of metformin, rapamycin, and their combination on growth and progression of prostate tumors in HiMyc mice. Cancer Prev Res (Phila). 2015; 8(7): 597–606.
   Google Scholar
• Fujishita T, Aoki K, Lane HA, Aoki M, Taketo MM. Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice. Proc Natl Acad Sci USA. 2008; 105: 13544–9.
   Google Scholar
• Piselli P, Serraino D, Segoloni GP, Sandrini S, Piredda GB, Scolari MP, etal. Risk of de novo cancers after transplantation: results from a cohort of 7217 kidney transplant recipients, Italy 1997–2009. Eur J Cancer. 2013; 49: 336–44.
   Google Scholar
• Houghton PJ. Everolimus. Clin Cancer Res. 2010; 16: 1368–72.
   Google Scholar
• Squillace RM, Miller D, Wardwell SD, Wang F, Clackson T, Rivera VM. Synergistic activity of the mTOR inhibitor ridaforolimus and the antiandrogen bicalutamide in prostate cancer models. Int J Oncol. 2012; 41(2): 425–32. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Proud CG. Control of the translational machinery by amino acids. Am J Clin Nutr. 2014; 99: 231–6.
   Web of Science ®Google Scholar
• Yip CK, Murata K, Walz T, Sabatini DM, Kang SA. Structure of the Human mTOR complex I and its implications for rapamycin inhibition. Mol Cell. 2010; 38: 768–74.
   Google Scholar
• Aylett CHS, Sauer E, Imseng S, Boehringer D, Hall MN, Ban N, etal. Architecture of human mTOR complex 1. Science. 2016; 351(6268): 48–52.
   Google Scholar
• Mamane Y, Petroulakis E, Rong L, Yoshida K, Ler LW, Sonenberg N. eIF4E – from translation to transformation. Oncogene. 2004; 23: 3172–9.
   Google Scholar
• Alain T, Sonenberg N, Topisirovic I. mTOR inhibitor efficacy is determined by the eIF4E/4E-BP ratio. Oncotarget. 2012; 3: 1491–2.
   Google Scholar
• Gentilella A, Kozma SC, Thomas G. A liaison between mTOR signaling, ribosome biogenesis and cancer. Biochim Biophys Acta Gene Regul Mech. 2015; 1849(7): 812–20.
   PubMed Web of Science ®Google Scholar
• Chauvin C, Koka V, Nouschi A, Mieulet V, Hoareau-Aveilla C, Dreazen A, etal. Ribosomal protein S6 kinase activity controls the ribosome biogenesis transcriptional program. Oncogene. 2014; 33(4): 474–83.
   Google Scholar
• Iadevaia V, Liu R, Proud CG. mTORC1 signaling controls multiple steps in ribosome biogenesis. Semin Cell Dev Biol. 2014; 36: 1–8.
   Web of Science ®Google Scholar
• Mayer C, Grummt I. Ribosome biogenesis and cell growth: mTOR coordinates transcription by all three classes of nuclear RNA polymerases. Oncogene. 2006; 25: 6384–91.
   Google Scholar
• Meyuhas O, Dreazen A. Ribosomal protein S6 kinase from TOP mRNAs to cell size. Prog Mol Biol Transl Sci. 2009; 90: 109–53. [PubMed Abstract].
   Google Scholar
• Khan MZI, Prebeg Ž, Kurjaković NA. pH-dependent colon targeted oral drug delivery system using methacrylic acid copolymers. I. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J Control Release. 1999; 58: 215–22.
   Google Scholar
• Albert V, Hall MN. mTOR signaling in cellular and organismal energetics. Curr Opin Cell Biol. 2015; 33: 55–66.
   Google Scholar
• Liao CY, Rikke BA, Johnson TE, Gelfond JAL, Diaz V, Nelson JF. Fat maintenance is a predictor of the murine lifespan response to dietary restriction. Aging Cell. 2011; 10: 629–39.
   Google Scholar
• Thoreen CC. Many roads from mTOR to eIF4F. Biochem Soc Trans. 2013; 41: 913–16.
   Google Scholar
• Furic L, Rong L, Larsson O, Koumakpayi IH, Yoshida K, Brueschke A, etal. eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci USA. 2010; 107(32): 14134–9.
   Google Scholar
• Ueda T, Sasaki M, Elia AJ, Chio IIC, Hamada K, Fukunaga R, etal. Combined deficiency for MAP kinase-interacting kinase 1 and 2 (Mnk1 and Mnk2) delays tumor development. Proc Natl Acad Sci USA. 2010; 107: 13984–90.
   Google Scholar
• Hou J, Kam F, Proud CG, Wang S, Lam F, Proud CG, etal. Targeting Mnks for cancer therapy. Oncotarget. 2012; 3(2): 118–31.
   Google Scholar
• Proud CG. Mnks, eIF4E phosphorylation and cancer. Biochim Biophys Acta. 2015; 1849(7): 766–73.
   Google Scholar
• Bianchini A, Loiarro M, Bielli P, Busà R, Paronetto MP, Loreni F, etal. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis. 2008; 29(12): 2279–88.
   Google Scholar
• Marzec M, Liu X, Wysocka M, Rook AH, Odum N, Wasik MA. Simultaneous inhibition of mTOR-containing complex 1 (mTORC1) and MNK induces apoptosis of cutaneous T-cell Lymphoma (CTCL) cells. PLoS One. 2011; 6(9): 2–9.
   Web of Science ®Google Scholar
• Sun SY, Rosenberg LM, Wang X, Zhou Z, Yue P, Fu H, etal. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005; 65: 7052–8.
   Google Scholar
• Wang X, Yue P, Chan C-B, Ye K, Ueda T, Watanabe-Fukunaga R, etal. Inhibition of mammalian target of rapamycin induces phosphatidylinositol 3-kinase-dependent and Mnk-mediated eukaryotic translation initiation factor 4E phosphorylation. Mol Cell Biol. 2007; 27(21): 7405–13.
   Google Scholar
• Zang C, Eucker J, Liu H, Müller A, Possinger K, Scholz CW. Concurrent inhibition of PI3-kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1. Cancer Lett. 2013; 339(2): 288–97.
   Google Scholar
• Alain T, Morita M, Fonseca BD, Yanagiya A, Siddiqui N, Bhat M, etal. eIF4E/4E-BP ratio predicts the efficacy of mTOR targeted therapies. Cancer Res. 2012; 72(24): 6468–76.
   Google Scholar
• Decarlo L, Mestel C, Barcellos-Hoff M-H, Schneider RJ. eIF4E is a Feed-forward translational coactivator of TGFβ early pro-transforming events in breast epithelial cells. Mol Cell Biol. 2015
   Web of Science ®Google Scholar
• O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, etal. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006; 66(3): 1500–8.
   Google Scholar
• Efeyan A, Sabatini DM. MTOR and cancer: many loops in one pathway. Curr Opin Cell Biol. 2010; 22(2): 169–76.
   Google Scholar
• Lamming DW, Mihaylova MM, Katajisto P, Baar EL, Yilmaz OH, Hutchins A, etal. Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan. Aging Cell. 2014; 13: 911–17.
   Google Scholar
• O'Leary MN, Schreiber KH, Zhang Y, Duc ACE, Rao S, Hale JS, etal. The ribosomal protein Rpl22 controls ribosome composition by directly repressing expression of its own paralog, Rpl22l1. PLoS Genet. 2013; 9(8): e1003708.
   Google Scholar
• Anderson SJ, Lauritsen JPH, Hartman MG, Foushee AMD, Lefebvre JM, Shinton SA, etal. Ablation of ribosomal protein L22 selectively impairs alphabeta T cell development by activation of a p53-dependent checkpoint. Immunity. 2007; 26(6): 759–72.
   Google Scholar
• Zhang Y, Duc A-CE, Rao S, Sun X-L, Bilbee AN, Rhodes M, etal. Control of hematopoietic stem cell emergence by antagonistic functions of ribosomal protein paralogs. Dev Cell. United States. 2013; 24(4): 411–25.
   Google Scholar
• Rao S, Lee S-Y, Gutierrez A, Perrigoue J, Thapa RJ, Tu Z, etal. Inactivation of ribosomal protein L22 promotes transformation by induction of the stemness factor, Lin28B. Blood. 2012; 120(18): 3764–73.
   Google Scholar
• Pérez-Ortín JE, Alepuz P, Chávez S, Choder M. Eukaryotic mRNA decay: methodologies, pathways, and links to other stages of gene expression. J Mol Biol. 2013; 425(20): 3750–75.
   PubMed Web of Science ®Google Scholar
• Henras AK, Plisson-Chastang C, O'Donohue M-F, Chakraborty A, Gleizes P-E. An overview of pre-ribosomal RNA processing in eukaryotes. Wiley Interdiscip Rev RNA. 2015; 6: 225–42.
   Google Scholar
• Nwagwu M, Nana M. Ribonucleic acid synthesis in embryonic chick muscle, rates of synthesis and half-lives of transfer and ribosomal RNA species. J Embryol Exp Morphol. 1980; 56: 253–67. [PubMed Abstract].
   Google Scholar
• Dai DF, Karunadharma PP, Chiao YA, Basisty N, Crispin D, Hsieh EJ, etal. Altered proteome turnover and remodeling by short-term caloric restriction or rapamycin rejuvenate the aging heart. Aging Cell. 2014; 13: 529–39.
   Google Scholar
• Yilmaz ÖH, Katajisto P, Lamming DW, Gültekin Y, Bauer-Rowe KE, Sengupta S, etal. mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature. 2012; 486(7404): 490–5. [PubMed Abstract] [PubMed CentralFull Text].
   Google Scholar
• Miller RA, Harrison DE, Astle CM, Floyd RA, Flurkey K, Hensley KL, etal. An aging interventions testing program: study design and interim report. Aging Cell. 2007; 6: 565–75.
   Google Scholar
• Harrison DE, Strong R, Allison DB, Ames BN, Astle CM, Atamna H, etal. Acarbose, 17-(-estradiol, and nordihydroguaiaretic acid extend mouse lifespan preferentially in males. Aging Cell. 2014; 13(2): 273–82.
   Google Scholar
• Flurkey K, Astle CM, Harrison DE. Life extension by diet restriction and N-acetyl-L-cysteine in genetically heterogeneous mice. J Gerontol A Biol Sci Med Sci. 2010; 65(12): 1275–84.
   Google Scholar